Thiazolidinediones and cardiovascular outcomes

British Journal of Diabetes and Vascular Disease

Volumn 8, Issue 1, 2008, Pages 45-49

  Barnett, Anthony H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Myocardial infarction; Pioglitazone; Rosiglitazone; Thiazolidinedione; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG FATALITY; EDEMA; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; METABOLIC DISORDER; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RISK REDUCTION; TREATMENT OUTCOME;

EID: 41349097968     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514080080011001     Document Type: Article

References (24)

1. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabetic Medicine 2006;23:579-93.
2. National Institute for Clinical Excellence. Management of type 2 diabetes: management of blood glucose. Inherited Clinical Guideline G; September 2002.
3. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002;25:1177-84.
4. Bonora E, Kiechl S, Willeit J et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care 2007; 30:318-24.
5. Strutton DR, Stang PE, Erbey JR, Lydick E. Estimated coronary heart disease attributable to insulin resistance in populations with and without type 2 diabetes mellitus. Am J Manag Care 2001; 7:765-73.
6. Actos®. Summary of product characteristics. August 2007. Available from:http://emc.medicines.org.uk/emc/industry/ default.asp?remoteSearch=Actos. Last accessed December 2007.
7. Actos®. US prescribing information. September 2007. Available from:http://www.actos.com/actospro/prescribinginfo.aspx. Last accessed December 2007.
8. Avandia®. US prescribing information. November 2007. Available from:http://us.gsk.com/products/assets/us_avandia.pdf. Last accessed December 2007.
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
10. Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting. N Engl J Med 2007;357:844-6.
11. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
12. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosigltazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
13. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
14. US Food and Drug Administration. FDA news. FDA adds boxed warning for heart-related rsks to anti-diabetes drug Avandia. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01743.html. Last accessed December 2007.
15. Avandia®. Summary of product characteristics. November 2007. Available from: http://emc.medicines.org.uk/emc/industry/ default.asp?remoteSearch=Avandia. Last accessed December 2007.
16. Bloomgarden ZT. The Avandia debate. Diabetes Care 2007; 30:2401-8.
17. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
18. Wilcox R, Bousser M-G, Betteridge J et al. for the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Stroke 2007;38:865-73.
19. Erdmann E, Dormandy JA, Charbonnel B et al. on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) study. J Am Coll Cardiol 2007;49:1772-80.
20. Xu Y, Vallarino C, Baran RW, Spanheimer R. Risk of stroke and myocardial infarction is reduced in patients with type 2 diabetes treated with pioglitazone: results of a retrospective, claims-based study. Diabetologia 2007;50(suppl 1):S513, Abstract 1257.
21. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8.
22. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54.
23. Derosa G, D'Angelo A, Ragonesi PD et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83.
24. American Diabetes Association. Complications of diabetes in the United States. Available from: http://www.diabetes.org/diabetes-statistics/ complications.jsp. Last accessed December 2007.